Free Trial

NIOX Group (LON:NIOX) Trading 1.4% Higher - Still a Buy?

NIOX Group logo with Medical background

Key Points

  • NIOX Group Plc shares increased by 1.4%, reaching GBX 73.40 ($0.99), significantly above the previous close of GBX 72.40 ($0.98).
  • The company's market capitalization is approximately £306.68 million, with a notably high PE ratio of 8,843.37.
  • Insider Ian Johnson bought 144,844 shares at an average price of GBX 8, reflecting continued confidence in the firm.
  • Five stocks we like better than NIOX Group.

NIOX Group Plc (LON:NIOX - Get Free Report) traded up 1.4% during mid-day trading on Thursday . The company traded as high as GBX 74 ($1.00) and last traded at GBX 73.40 ($0.99). 6,608,950 shares traded hands during trading, an increase of 503% from the average session volume of 1,096,099 shares. The stock had previously closed at GBX 72.40 ($0.98).

NIOX Group Price Performance

The company's 50 day simple moving average is GBX 70.77 and its 200 day simple moving average is GBX 68.03. The company has a current ratio of 6.31, a quick ratio of 1.94 and a debt-to-equity ratio of 1.10. The stock has a market capitalization of £307.52 million, a PE ratio of 8,867.47 and a beta of 0.92.

Insider Transactions at NIOX Group

In related news, insider Ian Johnson purchased 144,844 shares of the company's stock in a transaction that occurred on Wednesday, June 25th. The stock was purchased at an average price of GBX 8 per share, with a total value of £11,587.52. Insiders own 4.89% of the company's stock.

NIOX Group Company Profile

(Get Free Report)

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. Headquartered in the UK and listed on the London Stock Exchange ticker: NIOX, the company operates internationally, serving healthcare professionals in over 50 countries.

Further Reading

Should You Invest $1,000 in NIOX Group Right Now?

Before you consider NIOX Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NIOX Group wasn't on the list.

While NIOX Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.